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sensitivity analysis (PSA) results. METHODS: Decision analytic models were devel-
oped in Excel and R to assess the cost-effectiveness of a hypothetical therapy for a 
hypothetical, chronic disease. The models consisted of a decision tree (22 branches) 
for the ﬁrst year of therapy and of a Markov model to capture long-term costs and 
effects. Both models comprised 24 decision nodes and 6 Markov models. All costs, 
effectiveness and utility parameters were hypothetical. Probabilistic sensitivity analysis 
was used to assess decision uncertainty by performing 10 000 Monte Carlo simula-
tions. RESULTS: The incremental cost-effectiveness ratio (ICER) of the new therapy 
was $75,962.164371494/QALY when calculated with R and $75,962.164371494/
QALY when calculated with Excel. At a threshold value of $50,000 per QALY, the 
probability that the hypothetical treatment is cost-effective was 14.5% when calcu-
lated with Excel and 13.6% when using R. At the higher thresholds of $100,000 and 
$150 000 per QALY, the probabiliy estimates increased to 80.4% (Excel) and 80.6% 
(R) and 98.0% (Excel) and 98.1% (R), respectively. CONCLUSIONS: Excel and R 
allow building and analyzing complex decision models. As we showed, both model 
implementations yield the same results when calculating an ICER, up to 14 digits. The 
difference in PSA results might have been due to their probabilistic nature (here: 
10,000 iterations). Both packages have been used for medical decision making. Choos-
ing one package over the other does not need to be performance-based and can be 
left to personal preference.
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OBJECTIVES: Many cost-effectiveness analyses in rheumatoid arthritis (RA) rely on 
statistical models relating Health Assessment Questionnaire Disability Index (HAQ) 
scores to health utilities. Linear models can produce out-of-bound estimates of Health 
Utilities Index Mark 3 (HUI3) scores. We estimated bounded, nonlinear relationships 
between HAQ and HUI3 based on patient-level data. METHODS: Bayesian general-
ized linear models (GLMs) were developed to predict baseline HUI3 conditional on 
baseline HAQ using patient-level data from the PREMIER (2-year controlled study in 
early RA) and ARMADA (24-week controlled study in longstanding RA) trials. HUI3 
was rescaled to the interval [0,1] and modeled using a beta distribution and logistic 
link function. Normal-linear models were also estimated. Alternative speciﬁcations 
included age, sex, and HAQ-squared as additional predictors. Model parameters were 
estimated using WinBUGS 1.4.3. Models were compared using the deviance informa-
tion criterion (DIC); lesser values imply better ﬁt. Predicted values from beta-logistic 
models were linearly retransformed to the original HUI3 scale. RESULTS: Results 
were similar in early and late RA. Based on DIC, the beta-logistic models were more 
likely to generate the observed data than were the normal-linear models (PREMIER: 
–673.0 vs. –614.4; ARMADA: –226.1 vs. –215.8). Qualitatively, predictions from the 
beta-logistic models differed modestly from the normal-linear model. At low disability 
(HAQ  0.0), predicted HUI3 utilities were 0.75 vs. 0.81 (PREMIER) and 0.74 vs. 
0.79 (ARMADA) for the beta-logistic and normal-linear models, respectively. At high 
disability (HAQ  3.0), predicted HUI3 utilities were –0.03 vs. –0.05 (PREMIER) and 
0.01 vs. 0.01 (ARMADA). Age, sex, and HAQ-squared did not improve DIC. CON-
CLUSION: There is a strong negative relationship between HAQ and HUI3. Although 
the overall relationship is nonlinear, the linear approximation seems close across 
the relevant range of HAQ scores (0–3). Considering the complexity of the GLM 
approach, normal-linear regression may be adequate for cost-effectiveness analyses.
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OBJECTIVES: The analytic hierarchy process (AHP), a technique for multi-criteria 
decision analysis, is increasingly being used to support health care decision making. 
These decisions mainly relate to the application and coverage of health care technolo-
gies, and its use as a patient-reported outcome measure. The objective of this study is 
to review the use of this upcoming technique in health care; the Analytic Hierarchy 
Process. METHODS: We conducted a systematic review of the relevant medical, 
health-economical, psycho-sociological, managerial, and applied mathematical litera-
ture. We used the keywords “Analytic Hierarchy Process” AND (“patient” OR 
“patients” OR “health” OR “health care” OR “medical” OR “clinical” OR “hospi-
tal”) to search in the general topic of the articles within in the databases PubMed and 
Web of Science. RESULTS: We found 57 distinctive AHP applications in health care. 
Of the retrieved applications, 13 % focus on shared decision-making between patient 
and clinician, 25 % on the development of clinical practice guidelines, 5 % on the 
development of medical devices and pharmaceuticals, 44 % on management decisions 
in health care organizations, and 13 % on the development of national health care 
policy. CONCLUSIONS: From the review it is concluded that the AHP is frequently 
used and provides valuable support in complex health care decisions. The AHP is 
suitable to apply in case of complex health care decision problems, a need to improve 
decision making instead of explain decision outcomes, a need to share information 
among experts or between clinicians and patients, and in case of a limited availability 
of informed respondents. We also foresee the use of the AHP in conducting compre-
hensive Health Technology Assessments involving multiple stakeholders. Only for 
these speciﬁc types of decision problems, we recommend the use of the AHP.
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The Food and Drug Administration Amendments Act of 2007 requires FDA to develop 
and implement plans for evaluating beneﬁts and risks of new pharmaceuticals. Quan-
titative approaches to comparing therapeutic beneﬁts and risks thus are increasingly 
of interest to regulators and industry decision makers. OBJECTIVES: To quantify 
beneﬁt-risk tradeoff preferences for post-transplant outcomes among chronic kidney-
disease patients at risk for kidney transplant and estimate maximum acceptable 
adverse-event risks for speciﬁed efﬁcacy improvements. METHODS: US residents aged 
18 years or older with a self-reported diagnosis of chronic kidney failure or end-stage 
kidney disease completed a web-enabled survey instrument that presented a series of 
trade-off questions, each including a pair of hypothetical post-transplant outcome 
proﬁles. Each proﬁle was deﬁned by ﬁve efﬁcacy attributes and three life-threatening 
adverse-event attributes. Each subject answered 9 trade-off questions based on a pre-
determined experimental design with known statistical properties. RESULTS: A total 
of 233 subjects completed the survey. Subjects judged life expectancy to be more than 
three times more important than the next most important outcome. There were sig-
niﬁcant differences in preferences between older and younger subjects. Subjects over 
age 54 judged risks of impaired renal function, graft loss, acute rejection, infection, 
and malignancy as similarly important and progressive multifocal leukoencephalopa-
thy (PML) risk as much less important. Subjects under age 54 judged risks of acute 
rejection, malignancy, and PML as unimportant. Maximum acceptable risk of serious 
infection for a one-year increase in expected survival was 8.5% (5.1%–17.7%) and 
1.6% (0.9%–3.1%) for older and younger subjects, respectively. CONCLUSIONS: 
The beneﬁt-risk tradeoff data obtained in this study support valid estimates of 
maximum acceptable adverse-event risks in different patient populations. These esti-
mates of risk tolerance provide a useful quantitative approach to identifying treat-
ments where acceptable risk levels exceed actual risk levels by signiﬁcant margins.
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OBJECTIVES: Many patients experience complex disease courses raising concerns 
about fragmentation of care and continuity. The objective of the present study was 
to explore which dimensions that are important to patients in their experience of 
continuity of care. Patients’ preferences were elicited using a discrete choice experiment 
(DCE). METHODS: 1800 patients were invited to participate in a postal survey 
including three patient groups; diabetics, heart patients and cancer patients. Random 
samples of each of the deﬁned patient groups were recruited through Odense Univer-
sity Hospital given at least one admission during the last two years. The DCE con-
tained ﬁve attributes; 1) Involvement of GP in the patient’s course of disease; 2) 
Arrangement of a contact person at the hospital; 3) Involvement of the patient in the 
decisions; 4) Yearly consultation at hospital; and 5) Distance to hospital. RESULTS: 
Data was collected in the period April-June 2009 and resulted in an overall response 
rate of 67%. Primary analyses of DCE data are promising. All respondents value 
patient involvement in the treatment decision highly whereas the involvement of GPs 
matters less—in particular to diabetic patients and cancer patients. We observe some 
differences in preferences among diabetes compared to the two other patient groups. 
Notably heart and cancer patients ﬁnd the offer of yearly consultation unimportant 
and ﬁnd the arrangement of a contact person objectionable. These two differences 
likely indicate patients’ (dis)satisfaction with the health care system and the current 
organisation of treatment and as such may reﬂect some lack of continuity of care. 
CONCLUSIONS: Worldwide there has been a policy focus on enhancing patients’ 
satisfaction and enhancing continuity of care among patients. The present study con-
tributes to this work by examining what dimensions that are deemed important by 
patients in their experience with the health care system during their disease courses.
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The US Food and Drug Administration recently was granted new authority to regulate 
tobacco-related risks. While the morbidity and mortality beneﬁts of smoking cessation 
